Clinical trials: Lymphomas Non-Hodgkin's B-Cell
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Diffuse Large B-Cell Lymphoma
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the primary objective is to establish a maximum tolerated dose of Temsirolimus in combination with Rituximab and DHAP.
- Trial name
- STORM (NCT01653067)
- Testing
- Rituximab, Temsirolimus, DHAP, intravenous
- Where
- 9 sites in Germany
- Volunteers
- 88 people
- Sponsor
- Mathias Witzens-Harig
Lymphoma
AZD1152 in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma is the commonest type of aggressive non-Hodgkin's lymphoma, a type of cancer of a cell called a lymphocyte which makes up part of the immune system.
- Trial name
- NCT01354392
- Testing
- AZD1152
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Oxford University Hospitals NHS Trust
Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Expanded Access Program for Selinexor
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma
- Trial name
- KEAP (NCT07215832)
- Testing
- selinexor
- Sponsor
- Karyopharm Therapeutics Inc
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
This phase I trial is studying the side effects and best dose of vorinostat in treating patients with metastatic or unresectable solid tumors or lymphoma and liver dysfunction.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00499811
- Testing
- vorinostat, pharmacological study
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Trial name
- NCT00002941
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 69 people
- Sponsor
- Children's Oncology Group
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with carboplatin, etoposide, and rituximab in treating patients with diffuse large B cell lymphoma or Hodgkin…
- Trial name
- TREC (NCT01165112)
- Testing
- Bendamustine Hydrochloride, Carboplatin, Rituximab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
Experimental Bone Marrow Transplant Protocol
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00061581
- Testing
- Isolex 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells.
- Conditions
- Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma
- Trial name
- NCT06026319
- Testing
- CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Lymphoma, Mantle-Cell
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by…
- Trial name
- BRUIN-MCL-321 (NCT04662255)
- Testing
- Pirtobrutinib, Ibrutinib, Acalabrutinib
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 500 people
- Sponsor
- Loxo Oncology, Inc.
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004112
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
B Cell Lymphoma
Treatment of Aggressive Localized Lymphoma
Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.
- Trial name
- NCT00841945
- Testing
- rituximab, doxorubicin, vincristine
- Where
- France
- Volunteers
- 334 people
- Sponsor
- French Innovative Leukemia Organisation
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia
- Trial name
- NCT00963495
- Testing
- Clioquinol
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Lymphoma
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab with chemotherapy may kill more cancer cells.
- Trial name
- NCT00004039
- Testing
- recombinant interferon alfa, rituximab, cyclophosphamide
- Where
- United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Relapsed or Refractory B-cell Lymphoma
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
PD1 pathway is critical in determining the response to CAR T cell therapy. Emerging data suggested that Inhibition of PD1 could enhance the efficacy of CAR T cell therapy.
- Trial name
- NCT03208556
- Testing
- iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Mantle Zone Lymphoma Refractory/Recurrent
- Trial name
- NCT02981745
- Testing
- CT-1530
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Lymphoma
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00039195
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DLBCL - Diffuse Large B Cell Lymphoma
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
This is a Phase 1b study of participants with Diffuse Large B Cell Lymphoma (DLBCL). The purpose of this study is to identify an optimized lymphodenpletion (LD) regimen by evaluating standard and intermediate doses of Fludarabine…
- Trial name
- ODIN (NCT05950802)
- Testing
- Cyclophosphamide, TLI
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.